1 There
were no ablation-related changes in mechanical or heat withdr
2 plained by changes in metabolic rate, nor CO(2) , and there
were no changes in the HVR in normoxic mice.
3 Among smokers, there
were no clear associations between any of the exposures and e
4 There
were no clinically relevant treatment-related serious adverse
5 There
were no correlations with LGI1/CASPR2-IgG1-4 subclasses.
6 easibility study of the BEC for intermediate-risk PE, there
were no deaths or device-related adverse events and a signifi
7 on as low as one nanomolar, and at this concentration there
were no detectable effects on cell proliferation or viability
8 There
were no differences between women who initiated IPT antepartu
9 There
were no differences in 28- or 90-day mortality rates.
10 Among patients >=65 years old, there
were no differences in adjusted 1-year risks of adverse outco
11 There
were no differences in gender, BMI, % body fat, visual acuity
12 tcomes than patients with pulseless arrests, although there
were no differences in immediate event outcomes or intra-arre
13 In Langendorff-perfused hearts, there
were no differences in mean action potential duration (APD(80
14 There
were no differences in outcomes between standard dose of epin
15 ers for 3 of 18 pseudoviruses examined (P < .05), but there
were no differences in overall NAb breadth (P = .62).
16 greater in Taz(KD) than in wild-type (WT) hearts, but there
were no differences in oxidative phosphorylation coupling eff
17 There
were no differences in patient demographics, IDH/MGMT mutatio
18 Below 10 ug/ml, there
were no dose-dependent cellular ROS increases or effects in M
19 There
were no drug-related serious adverse events and no treatment-
20 Exclusion critiera at admission
were no fetal heartbeat heard or imminent birth.
21 There
were no group differences on subjective reports of bad or unp
22 There
were no intra-abdominal abscess in either groups.
23 timated the treatment delay times at which half of the AGMs
were no longer expected to survive as 19.7 hours for ciproflo
24 At 10 years, there
were no measurable differences in outcomes between patients t
25 Patients
were no more likely to acquire MRSA if they were cared for us
26 Further, there
were no ocular serious AEs (SAEs) and no cases of endophthalm
27 There
were no other statistically significant differences.
28 There
were no postoperative complications or failure to observe the
29 There
were no significant benefits of medication on likelihood of s
30 There
were no significant between-group differences in both worst a
31 There
were no significant between-group differences in serious adve
32 There
were no significant changes about lung function test, smoking
33 Although there
were no significant changes in the recession depth between 3
34 At 6 months, there
were no significant differences between the injection (n = 38
35 At both 6 and 12 months, however, there
were no significant differences for these variables and no si
36 There
were no significant differences in any of the secondary outco
37 There
were no significant differences in clinical outcomes between
38 There
were no significant differences in health care use or missed
39 There
were no significant differences in leptin (-0.7 ng/mL; -2.1,
40 There
were no significant differences in measures of mitochondrial
41 There
were no significant differences in peak heart rate response d
42 Overall, there
were no statistically significant benefits of any interventio
43 However, there
were no statistically significant differences in handgrip str
44 There
were no statistically significant improvements in insulin sen
45 By a post hoc analysis, there
were no statistically significant increases from week 52 to w
46 Though there
were no statistically significant increases in KS rates in an
47 There
were no strong correlations between the pathophysiologies and
48 There
were no therapy effects on the second standardised co-primary
49 Respiration acclimated to elevated temperatures, but there
were no treatment effects on the Q(10) of respiration (the in
50 There
were no unexpected adverse events with (177)Lu-PSMA retreatme